Alto Neuroscience to Participate in Upcoming Investor Conferences

Audio By Carbonatix

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aug 18, 2025--

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events:

• H.C. Wainwright Biotech Breakthroughs: Precision Neuropsychiatry Panel
  • Format: Panel discussion
  • Presentation Date & Time: Thursday, August 21, 2025, at 10:00 am ET
• H.C. Wainwright 27 th Annual Global Investment Conference, September 8-10 th 2025:
  • Format: Fireside chat and one-on-one investor meetings
  • Presentation Date & Time: Tuesday, September 9, 2025, at 2:00 pm ET
  • Location: Lotte New York Palace Hotel
• Baird 2025 Global Healthcare Conference, September 9-10 th 2025:
  • Format: Presentation and one-on-one investor meetings
  • Presentation Date & Time: Wednesday, September 10, 2025, at 8:30 am ET
  • Location: InterContinental New York
• TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, September 17-18 th 2025:
  • Format: Fireside chat and one-on-one investor meetings
  • Presentation Date & Time: Wednesday, September 17, 2025, at 1:20 pm ET

Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250818230905/en/

CONTACT: Investor Contact:

Nick Smith

[email protected] Contact:

Mari Purpura

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY NEUROLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Alto Neuroscience, Inc.

Copyright Business Wire 2025.

PUB: 08/18/2025 08:03 AM/DISC: 08/18/2025 08:03 AM

http://www.businesswire.com/news/home/20250818230905/en